Tocilizumab for systemic juvenile idiopathic arthritis

New England Journal of Medicine

Volumn 368, Issue 13, 2013, Pages 1256-1257

  Hagino, Noboru ^a   Yamaguchi, Ken Ichi ^b   Ohara, Yuri ^b  

^a TEIKYO UNIVERSITY CHIBA MEDICAL CENTER   (Japan)

^b ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; GAMMA INTERFERON; GLUCOCORTICOID; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; PLACEBO; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA; INTERLEUKIN 6 RECEPTOR; MONOCLONAL ANTIBODY; INTERLEUKIN 1;

CYTOKINE STORM; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LETTER; MACROPHAGE ACTIVATION SYNDROME; OPEN STUDY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; DRUG ANTAGONISM; FEMALE; MALE; NOTE; CLINICAL PRACTICE; CYTOKINE RESPONSE; DRUG CONTRAINDICATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; NEUTROPENIA; NONHUMAN; SIDE EFFECT; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, JUVENILE RHEUMATOID; FEMALE; HUMANS; MALE; RECEPTORS, INTERLEUKIN-6;

EID: 84875536558     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1301017     Document Type: Letter

References (4)

1. De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012;367:2385-95.
2. Vastert SJ, Kuis W, Grom AA. Systemic JIA: new developments in the understanding of the pathophysiology and therapy. Best Pract Res Clin Rheumatol 2009;23:655-64.
3. Shimizu M, Nakagishi Y, Kasai K, et al. Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: the diagnostic significance of interleukin-18 and interleukin-6. Cytokine 2012;58:287-94.
4. Ravelli A. Macrophage activation syndrome. Curr Opin Rheumatol 2002;14:548-52. (Pubitemid 34953793)